A Progressive Resistance Training Program in Patients With Haemophilia

Sponsor
University of Valencia (Other)
Overall Status
Completed
CT.gov ID
NCT02781233
Collaborator
Shire (Industry)
20
1
2
8
2.5

Study Details

Study Description

Brief Summary

This study evaluates the clinical impact of a progressive resistance training program in adults patients with haemophilia

Condition or Disease Intervention/Treatment Phase
  • Other: Progressive resistance training
  • Other: Normal daily activities
N/A

Detailed Description

The training program aims improving muscular strength and endurance in the relevant muscles and joints (knee, elbow, ankle, shoulder and hip) in order to improve the quality of life in the patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Impact of Progressive Resistance Training on Quality of Life in Patients With Haemophilia
Actual Study Start Date :
Oct 24, 2017
Actual Primary Completion Date :
Jun 25, 2018
Actual Study Completion Date :
Jun 25, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Training group

Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.

Other: Progressive resistance training
Progressive resistance training program

Placebo Comparator: Control group

Usual daily activities

Other: Normal daily activities
Usual daily activities

Outcome Measures

Primary Outcome Measures

  1. Change in Muscle strength [baseline and 8 weeks]

    For measuring the isometric knee flexion and extension, ankle plantarflexion and dorsiflexion strength and isometric elbow flexion and extension strength, a portable hand-held dynamometer will be used (Nicholas Manual Muscle Tester, Lafayette Instruments, Indiana, USA).

Secondary Outcome Measures

  1. Change in Timed Up and Go [baseline and 8 weeks]

    The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.

  2. Change in Haemophilia Quality of life questionnaire (A36 Haemophilia-QoL® ) [baseline and 8 weeks]

    The Haemophilia-QoL questionnaire is a self-report modular instrument that assesses nine relevant HRQoL domains for patients with haemophilia (e.g. physical health, daily activities, joint damage, pain, treatment satisfaction, treatment difficulties, emotional functioning, mental health, relationships and social activity).

  3. Change in Bleedings [daily (during the 8 weeks of intervention)]

    Number of Bleedings During the study

  4. Change in viscoelastic properties (rectus femoris) [baseline and 8 weeks]

    Myoton Pro

  5. Change in sit-to-stand test [baseline and 8 weeks]

    The time taken for the participant to stand up and sit down from a standard 45 cm chair with arms three times, as quickly as possible, was measured.

  6. Change in Haemophilia Activities List questionnaire [baseline and 8 weeks]

    The Haemophilia Activities List questionnaire measures the impact of hemophilia on self-perceived functional abilities in adults. It contains 42 multiple choice questions in seven domains: Lying/sitting/kneeling/standing (8 items) Functions of the legs (9 items) Functions of the arms (4 items) Use of transportation (3 items) Self-care (5 items) Household tasks (6 items) Leisure activities and sports (7 items) The most important outcomes are the overall sum score and three component scores relating to upper extremity activities, basic lower extremity activities, and complex lower extremity activities. A domain score for each of the seven domains can also be calculated.

  7. Change in The Haemophilia Joint Health Score (HJHS) [baseline and 8 weeks]

    The HJHS measures joint health, in the domain of body structure and function (i.e. impairment), of the joints most commonly affected by bleeding in hemophilia: the knees, ankles, and elbows.The HJHS 2.1 provides a total score (higher score is worse; max=124), joint specific scores, and a global gait score.

  8. Change in Pain [baseline and 8 weeks]

    11-point numerical pain rating scale with higher score meaning higher pain

  9. Change in workability index [baseline and 8 weeks]

    workability index with single question

  10. Change in analgesics use (days/week) [baseline and 8 weeks]

    The number of days the participants used analgesics during the last week

  11. Change in Range Of Motion (ROM) [baseline and 8 weeks]

    elbow extensio/flexion, ankle dorsiflexion/plantar flexion and knee flexion/extension ROM with a goniometer

  12. Change in Kinesiophobia [baseline and 8 weeks]

    Tampa Scale of Kinesiophobia (TSK-11SV) used to assess changes in fear of movement

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • diagnosis of haemophilia A or B

  • willingness to exercise twice a week during the training program and to complete the pre- and post-program evaluations

  • approval by their hematologist to participate in the exercise program

  • age between 18 and 60 years

  • informed consent signed.

Exclusion Criteria:
  • the inability to attend exercise sessions at least twice a week for 6 consecutive weeks

  • non adherence to instruction on proper exercise technique

  • surgical procedures performed 6 weeks prior to or during the exercise program

  • participation in any other form of exercise, including rehabilitation, during the study; (5) changes in medication during the study

  • a major bleeding episode that posed a risk or prevented exercise

  • History of FVIII inhibitor (titer ≥ 0.6 BU [Bethesda unit]) or detectable FVIII inhibitors at screening (titer ≥ 0.4 BU)

  • Another haemostatic defect

  • Need for major surgery

  • Withdrawal of informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Valencia Valencia Spain 46010

Sponsors and Collaborators

  • University of Valencia
  • Shire

Investigators

  • Principal Investigator: Felipe Querol-Fuentes, MD, PhD, University of Valencia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Felipe Querol Fuentes, Medical doctor, PhD, University of Valencia
ClinicalTrials.gov Identifier:
NCT02781233
Other Study ID Numbers:
  • H15-29504
First Posted:
May 24, 2016
Last Update Posted:
Oct 18, 2018
Last Verified:
Oct 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 18, 2018